From 1998 to 1999, researchers at the University of California, San Francisco, School of Medicine prepared a background paper on the risks and benefits of using nicotine replacement therapies and other smoking-cessation aids approved by the Food and Drug Administration (FDA) to treat pregnant smokers.
There is growing evidence that these smoking cessation aids can double the usual smoking quit rates achieved through self-help programs.
This project consisted of a literature review and critical analysis of the potential risks and benefits of using FDA-approved pharmacological quitting aids, including reviews of published and pre-publication research reports and FDA materials.
The paper, entitled Risks and Benefits of Nicotine and Other Medications to Aid Smoking Cessation in Pregnancy, focused on smoking cessation during pregnancy and lactation.
The paper was presented at a May 1999 conference on the "Use of Pharmacotherapies for Smoking Cessation during Pregnancy," sponsored by the RWJF national program Smoke-Free Families and the National Institute of Child Health and Human Development.
The paper was also accepted for publication in Drug Safety and sent to the FDA and several researchers in the field.